Gritstone bio, Inc. (GRTS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Gritstone bio, Inc. (GRTS)
Company Performance

Current Price

as of Oct 16, 2024

$0.06

P/E Ratio

N/A

Market Cap

$7.09M

Description

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.

Metrics

Overview

  • HQEmeryville, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerGRTS
  • Price$0.06-12.54%

Trading Information

  • Market Cap$7.09M
  • Float93.31%
  • Average Daily Volume (1m)45,277,643
  • Average Daily Volume (3m)15,485,497
  • EPS-$1.15

Company

  • Revenue$0.50M
  • Rev Growth (1yr)-85.75%
  • Net Income-$23.40M
  • Gross Margin-2,707.02%
  • EBITDA Margin-47,108.77%
  • EBITDA-$26.85M
  • EV$134.05M
  • EV/Revenue270.26
  • P/EN/A
  • P/S17.33
  • P/B0.32
Documents